3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
8
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Interventions
Temozolomide
14
Radiotherapy
14
Carboplatin
7
Irinotecan
6
Everolimus
5
Filgrastim
4
Carmustine
4
Surgical Procedures, Operative
3
Radiation
3
Paclitaxel
3
Ifosfamide
3
selpercatinib
2
pembrolizumab
2
Trastuzumab
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Methotrexate
2
Imatinib Mesylate
2
IL13-PE38
2
Dasatinib
2
Chemotherapy, Adjuvant
2
Bevacizumab
2
vitespin
1
veliparib
1
vatalanib
1
transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38)
1
tipifarnib
1
terameprocol
1
temsirolimus
1
talazoparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Central Nervous System Neoplasms
×
elacestrant
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled